Intellipharmaceutics Expands Drug Commercialization Expertise

TORONTO, Feb. 7, 2011 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced it has retained the services of Doll Consulting, LLC and its principal, David S. Doll, to assist the Company with the commercialization of products in its controlled-release generic drug portfolio and its 505(b)(2) New Drug Application (NDA) portfolio. Mr. Doll has [...] http://bit.ly/fxY0CP